76.04

1.21% 0.91

Edwards Lifesciences Corp (EW)

Overview News Price History Option Chain Financials Why EW Down? Discussions Forecast Stock Split

Edwards Lifesciences Corp stock is traded at $76.04, with a volume of 6.33M. It is up +1.21% in the last 24 hours and up +6.74% over the past month. Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.

Previous Close:

$75.13

Open:

$74.82

24h Volume:

6.33M

Relative Volume:

1.40

Market Cap:

$40.53B

Revenue:

$5.54B

Net Income/Loss:

$4.18B

P/E Ratio:

10.86

EPS:

Net Cash Flow:

$259.90M

1W Performance:

+6.31%

1M Performance:

+6.74%

6M Performance:

+9.60%

1Y Performance:

-13.60%

1-Day Range:

$74.10

$76.10

1-Week Range:

$68.63

$76.29

52-Week Range:

$58.93

$95.25

Edwards Lifesciences Corp Stock (EW) Company Profile

Name

Edwards Lifesciences Corp

Sector

Healthcare (1154)

Industry

Medical Devices (156)

Phone

(949) 250-2500

Address

ONE EDWARDS WAY, IRVINE, CA

Employee

15,800

Twitter

@edwardslifesci

Next Earnings Date

2025-02-11

Latest SEC Filings

EW's Discussions on Twitter

Compare EW with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
EW Edwards Lifesciences Corp	76.04	40.53B	5.54B	4.18B	259.90M	7.00
ABT Abbott Laboratories	128.85	225.27B	41.95B	13.40B	6.35B	7.65
BSX Boston Scientific Corp	101.90	138.41B	17.55B	2.03B	2.37B	1.37
SYK Stryker Corp	365.06	129.62B	22.60B	2.99B	3.49B	7.76
MDT Medtronic Plc	84.16	107.92B	33.20B	4.26B	5.47B	3.29

Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-30-25	Upgrade	Stifel	Hold → Buy
Jan-16-25	Downgrade	Wolfe Research	Peer Perform → Underperform
Dec-16-24	Upgrade	BofA Securities	Neutral → Buy
Oct-11-24	Resumed	Morgan Stanley	Equal-Weight
Sep-18-24	Downgrade	Jefferies	Buy → Hold
Jul-31-24	Upgrade	Daiwa Securities	Neutral → Outperform
Jul-29-24	Upgrade	Wolfe Research	Underperform → Peer Perform
Jul-25-24	Downgrade	BofA Securities	Buy → Neutral
Jul-25-24	Downgrade	JP Morgan	Overweight → Neutral
Jul-25-24	Downgrade	Robert W. Baird	Outperform → Neutral
Jul-25-24	Downgrade	TD Cowen	Buy → Hold
Jul-25-24	Downgrade	Truist	Buy → Hold
May-30-24	Initiated	Goldman	Buy
May-22-24	Upgrade	Citigroup	Neutral → Buy
May-14-24	Upgrade	Deutsche Bank	Hold → Buy
Mar-07-24	Upgrade	BofA Securities	Neutral → Buy
Feb-02-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Jan-04-24	Downgrade	Evercore ISI	Outperform → In-line
Dec-11-23	Downgrade	Citigroup	Buy → Neutral
Nov-28-23	Downgrade	Wolfe Research	Peer Perform → Underperform
Sep-26-23	Upgrade	Oppenheimer	Perform → Outperform
Jul-19-23	Initiated	Robert W. Baird	Outperform
May-30-23	Resumed	Morgan Stanley	Overweight
Mar-29-23	Initiated	UBS	Neutral
Mar-08-23	Downgrade	Wells Fargo	Overweight → Equal Weight
Feb-06-23	Downgrade	Raymond James	Outperform → Mkt Perform
Jan-31-23	Downgrade	Bernstein	Outperform → Underperform
Jan-30-23	Downgrade	Piper Sandler	Overweight → Neutral
Dec-06-22	Downgrade	Stifel	Buy → Hold
Oct-28-22	Downgrade	Oppenheimer	Outperform → Perform
Oct-26-22	Initiated	Mizuho	Buy
Oct-18-22	Initiated	Barclays	Overweight
Oct-12-22	Initiated	Jefferies	Buy
Jul-29-22	Downgrade	Canaccord Genuity	Buy → Hold
Apr-13-22	Initiated	Truist	Buy
Apr-06-22	Initiated	Wolfe Research	Outperform
Mar-16-22	Upgrade	Bernstein	Mkt Perform → Outperform
Mar-02-22	Resumed	BofA Securities	Neutral
Feb-02-22	Upgrade	UBS	Neutral → Buy
Jan-27-22	Reiterated	Citigroup	Buy
Jan-27-22	Reiterated	Evercore ISI	Outperform
Jan-27-22	Reiterated	Raymond James	Outperform
Jan-27-22	Reiterated	Stifel	Buy
Jan-27-22	Reiterated	UBS	Neutral
Dec-17-21	Upgrade	JP Morgan	Neutral → Overweight
Dec-15-21	Upgrade	Citigroup	Neutral → Buy
Dec-10-21	Initiated	RBC Capital Mkts	Outperform
Dec-06-21	Upgrade	Wells Fargo	Equal Weight → Overweight
Jul-30-21	Reiterated	Canaccord Genuity	Buy
Jul-30-21	Reiterated	Deutsche Bank	Hold
Jul-30-21	Reiterated	Jefferies	Buy
Jul-30-21	Reiterated	Morgan Stanley	Overweight
Jul-30-21	Reiterated	Oppenheimer	Outperform
Jul-30-21	Reiterated	Stifel	Buy
Jul-30-21	Reiterated	UBS	Neutral
Jul-30-21	Reiterated	Wells Fargo	Equal Weight
May-25-21	Initiated	Barclays	Overweight
Apr-15-21	Initiated	Atlantic Equities	Neutral
Apr-05-21	Upgrade	Evercore ISI	In-line → Outperform
Dec-16-20	Downgrade	Citigroup	Buy → Neutral
Dec-11-20	Reiterated	Canaccord Genuity	Buy
Sep-11-20	Initiated	Wolfe Research	Underperform
Apr-28-20	Downgrade	Wells Fargo	Overweight → Equal Weight
Apr-17-20	Upgrade	SVB Leerink	Mkt Perform → Outperform
Mar-05-20	Initiated	Citigroup	Buy
Feb-13-20	Initiated	Goldman	Neutral
Feb-06-20	Resumed	BTIG Research	Neutral
Jan-10-20	Initiated	Oppenheimer	Outperform
Jan-02-20	Downgrade	Evercore ISI	Outperform → In-line
Oct-24-19	Reiterated	Canaccord Genuity	Buy
Sep-23-19	Initiated	Piper Jaffray	Overweight
Jul-24-19	Reiterated	BofA/Merrill	Buy
Mar-18-19	Reiterated	Canaccord Genuity	Buy
Jan-18-19	Upgrade	BofA/Merrill	Neutral → Buy
Jan-03-19	Initiated	Deutsche Bank	Hold
Nov-28-18	Initiated	UBS	Neutral
Oct-16-18	Initiated	Barclays	Underweight
Oct-02-18	Downgrade	BofA/Merrill	Buy → Neutral
Oct-02-18	Downgrade	Guggenheim	Buy → Neutral

View All

Edwards Lifesciences Corp Stock (EW) Latest News

Apr 25, 2025

Edwards Lifesciences Reports Robust Q1 2025 Growth - TipRanks

Apr 25, 2025

Edwards Lifesciences (EW) Price Target Raised by Canaccord Analy - GuruFocus

Apr 25, 2025

Apr 24, 2025

Edwards Lifesciences Stock Earns Analyst Upgrade As Growth Outlook Brightens - Benzinga

Apr 24, 2025

Edwards Lifesciences (NYSE:EW) Projects 2025 Sales Over US$5.7 Billion With Strong Earnings - Yahoo Finance

Apr 24, 2025